Exclusivity versus Collaboration: Which is Best for Successful Clinical Trials?

In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.

YPrime announces a new report unveiling the top challenges that clinical trial executives face when implementing eCOA, and what to look for when evaluating new solutions.

Digital biomarkers provide a pathway to the future where clinical trial sponsors can potentially benefit from reduced trial duration and sample size. Learn more about these benefits from a simulated study.

Digital biomarkers, smartphones, and wearables are transforming clinical trials by revolutionizing remote data collection and providing insights into treatment efficacy. Learn more about these exploratory endpoints and how they provide greater confidence in a clinical trial.